Skip to main content
OTCMKTS:GBLX

GB Sciences News Headlines

$0.04
-0.01 (-20.00 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.03
$0.05
50-Day Range
$0.05
$0.06
52-Week Range
$0.02
$0.13
Volume3.49 million shs
Average Volume779,470 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

GB Sciences (OTCMKTS GBLX) News Headlines Today

SourceHeadline
GB Sciences (OTCMKTS:GBLX) Stock Passes Below 50 Day Moving Average of $0.06GB Sciences (OTCMKTS:GBLX) Stock Passes Below 50 Day Moving Average of $0.06
americanbankingnews.com - May 13 at 2:54 AM
GB Sciences, Inc. (OTCMKTS:GBLX) Sees Large Decrease in Short InterestGB Sciences, Inc. (OTCMKTS:GBLX) Sees Large Decrease in Short Interest
americanbankingnews.com - April 30 at 3:04 PM
GB Sciences Featured & Speaking at the SACHS Associates 4th Annual Neuroscience Innovation ForumGB Sciences Featured & Speaking at the SACHS Associates' 4th Annual Neuroscience Innovation Forum
finance.yahoo.com - April 27 at 9:33 AM
GB Sciences, Inc.: GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing PharmaceuticalsGB Sciences, Inc.: GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals
finanznachrichten.de - April 20 at 9:15 AM
GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing PharmaceuticalsGB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals
finance.yahoo.com - April 20 at 9:15 AM
GB Sciences, Inc.: GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery PlatformGB Sciences, Inc.: GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery Platform
finanznachrichten.de - April 7 at 10:41 AM
GB Sciences Publishes Study on Creation of Novel Terpene-Containing Nanoparticles for Pain ReliefGB Sciences Publishes Study on Creation of Novel Terpene-Containing Nanoparticles for Pain Relief
finance.yahoo.com - March 23 at 9:34 AM
GB Sciences Begins Proof of Concept Studies with Michigan State University for the Treatment of Cytokine Release SyndrGB Sciences Begins Proof of Concept Studies with Michigan State University for the Treatment of Cytokine Release Syndr
bloomberg.com - January 27 at 11:16 PM
GB Sciences Begins Proof of Concept Studies with Michigan State University for the Treatment of Cytokine Release SyndromeGB Sciences Begins Proof of Concept Studies with Michigan State University for the Treatment of Cytokine Release Syndrome
finance.yahoo.com - January 25 at 8:15 AM
News for GB Sciences Inc Registered ShsNews for GB Sciences Inc Registered Shs
markets.businessinsider.com - December 24 at 8:43 AM
GB Sciences, Inc.: GB Sciences Announces Issuance of US Patent for its Proprietary, Cannabinoid-Based Anti-Inflammatory FormulationsGB Sciences, Inc.: GB Sciences Announces Issuance of US Patent for its Proprietary, Cannabinoid-Based Anti-Inflammatory Formulations
finanznachrichten.de - December 9 at 10:53 PM
GB Sciences Announces Issuance of US Patent for its Proprietary, Cannabinoid-Based Anti-Inflammatory FormulationsGB Sciences Announces Issuance of US Patent for its Proprietary, Cannabinoid-Based Anti-Inflammatory Formulations
finance.yahoo.com - December 8 at 5:18 PM
GB Sciences Inc (GBLX)GB Sciences Inc (GBLX)
nasdaq.com - October 22 at 12:36 AM
GB Sciences Announces Issuance of US Patent for Its Proprietary Pain Formulations for the 560 Billion Dollar Chronic PGB Sciences Announces Issuance of US Patent for Its Proprietary Pain Formulations for the 560 Billion Dollar Chronic P
bloomberg.com - October 1 at 7:28 PM
GB Sciences Files Provisional Patent Application for the Treatment of COVID-19-Related Acute Respiratory Distress SyndGB Sciences Files Provisional Patent Application for the Treatment of COVID-19-Related Acute Respiratory Distress Synd
bloomberg.com - August 29 at 7:03 PM
GB Sciences Files Provisional Patent Application for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome (ARDS), the Leading Cause of Hospitalization and Deaths, Utilizing Its Cannabinoid Containing Complex Mixtures (CCCM(TM))GB Sciences Files Provisional Patent Application for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome (ARDS), the Leading Cause of Hospitalization and Deaths, Utilizing Its Cannabinoid Containing Complex Mixtures (CCCM(TM))
finance.yahoo.com - August 26 at 12:52 PM
GB Sciences secures U.S. patent covering pain compositionsGB Sciences secures U.S. patent covering pain compositions
seekingalpha.com - July 20 at 4:02 PM
GB Sciences Announces Issuance of US Patent for Its Proprietary Pain Formulations for the 560 Billion Dollar Chronic Pain Treatment MarketGB Sciences Announces Issuance of US Patent for Its Proprietary Pain Formulations for the 560 Billion Dollar Chronic Pain Treatment Market
finance.yahoo.com - July 20 at 11:01 AM
Catalent Selected to Provide Oral Delivery Systems for GB Sciences Proprietary Parkinsons Disease TherapiesCatalent Selected to Provide Oral Delivery Systems for GB Sciences' Proprietary Parkinson's Disease Therapies
www.bloomberg.com - July 16 at 12:05 PM
GB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinsons DiseasGB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinson's Diseas
www.bloomberg.com - June 9 at 6:51 PM
GB Sciences, Inc.: GB Sciences Announces Issuance of US Patent for Its Proprietary Cannabinoid-Based Formulations for Parkinsons DiseaseGB Sciences, Inc.: GB Sciences Announces Issuance of US Patent for Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease
www.finanznachrichten.de - May 4 at 9:32 AM
GB Sciences Announces Issuance of US Patent for Its Proprietary Cannabinoid-Based Formulations for Parkinsons DiseaseGB Sciences Announces Issuance of US Patent for Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease
finance.yahoo.com - May 4 at 9:32 AM
A Snapshot Of Americas Medical Marijuana Markets: LouisianaA Snapshot Of America's Medical Marijuana Markets: Louisiana
www.benzinga.com - April 9 at 2:08 PM
GB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinsons Disease Cannabinoid Formulations and Begins Mechanism of Action Study With the National Research Council of CanadaGB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinson's Disease Cannabinoid Formulations and Begins Mechanism of Action Study With the National Research Council of Canada
finance.yahoo.com - April 6 at 2:59 PM
History Made! GB Sciences Louisiana Announces Medical Cannabis Products Now for Sale for First Time in State HistoryHistory Made! GB Sciences Louisiana Announces Medical Cannabis Products Now for Sale for First Time in State History
www.bloomberg.com - March 28 at 9:06 PM
GB Sciences One of Ten Companies Named in Important New Canadian Research PublicationGB Sciences One of Ten Companies Named in Important New Canadian Research Publication
www.bloomberg.com - March 21 at 1:37 PM
GB Sciences Acquisition Of NevadaPURE Is TerminatedGB Sciences' Acquisition Of NevadaPURE Is Terminated
www.bloomberg.com - March 19 at 12:54 PM
GB Sciences Announces Outstanding Results from Preclinical Study of Its Parkinson's Disease FormulationsGB Sciences Announces Outstanding Results from Preclinical Study of Its Parkinson's Disease Formulations
finance.yahoo.com - December 20 at 2:01 PM
GB Sciences Announces the Sale of The Majority Interest in Nevada Cultivation Operations to Focus on Its First Two Cannabinoid-Based Medical Compounds for Parkinsons Disease and Neuropathic PainGB Sciences Announces the Sale of The Majority Interest in Nevada Cultivation Operations to Focus on Its First Two Cannabinoid-Based Medical Compounds for Parkinson's Disease and Neuropathic Pain
finance.yahoo.com - December 5 at 1:10 PM
GB Sciences Closes the Sale of GB Sciences Louisiana Cannabis Business to Wellcana Plus and Retains the Benefit of IP Developed Under GB Sciences Louisianas Master Research and Development AgreementGB Sciences Closes the Sale of GB Sciences Louisiana Cannabis Business to Wellcana Plus and Retains the Benefit of IP Developed Under GB Sciences Louisiana's Master Research and Development Agreement
finance.yahoo.com - November 18 at 10:36 AM
The Closing Date of GB Sciences Sale of GB Sciences Louisiana LLC Is DelayedThe Closing Date of GB Sciences' Sale of GB Sciences Louisiana LLC Is Delayed
finance.yahoo.com - November 6 at 7:14 AM
GB Sciences Welcomes Esteemed Patent and Intellectual Property Attorney, Mr. Edmond DeFrank, to Its Board of DirectorsGB Sciences Welcomes Esteemed Patent and Intellectual Property Attorney, Mr. Edmond DeFrank, to Its Board of Directors
finance.yahoo.com - October 31 at 7:48 PM
GB Sciences Inc.GB Sciences Inc.
www.barrons.com - October 13 at 12:03 AM
GB Sciences Sells Its Louisiana Medical Marijuana Business At A $32 Million Total ValuationGB Sciences Sells Its Louisiana Medical Marijuana Business At A $32 Million Total Valuation
finance.yahoo.com - September 17 at 4:08 PM
U.S. Drug Enforcement Agency to Expand Cannabis...U.S. Drug Enforcement Agency to Expand Cannabis...
www.benzinga.com - September 3 at 3:23 PM
GB Sciences receives DEA notice to regulate marijuana supplyGB Sciences receives DEA notice to regulate marijuana supply
seekingalpha.com - September 3 at 7:43 AM
U.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana ResearchersU.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers
finance.yahoo.com - September 3 at 7:43 AM
New Executive VP for Operations at GB SciencesNew Executive VP for Operations at GB Sciences
seekingalpha.com - August 28 at 11:28 AM
GB Sciences Names Darin Carpenter as Executive Vice President of Cannabis OperationsGB Sciences Names Darin Carpenter as Executive Vice President of Cannabis Operations
finance.yahoo.com - August 28 at 11:28 AM
GB Sciences Prepares To Launch New Products In Louisiana With Educational Seminars For Doctors And PharmacistsGB Sciences Prepares To Launch New Products In Louisiana With Educational Seminars For Doctors And Pharmacists
finance.yahoo.com - August 7 at 11:52 AM
GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived IngredientsGB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients
finance.yahoo.com - June 19 at 11:46 AM
GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain TherapiesGBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies
finance.yahoo.com - June 5 at 6:53 AM
GB Sciences to triple production capabilities at Las Vegas facilityGB Sciences to triple production capabilities at Las Vegas facility
seekingalpha.com - May 14 at 8:02 AM
GB Sciences Prepares to Triple Production Capabilities in Its Las Vegas FacilityGB Sciences Prepares to Triple Production Capabilities in Its Las Vegas Facility
finance.yahoo.com - May 14 at 8:02 AM
GB Sciences Louisianas cannabis operations now open at LSU agricultural centerGB Sciences Louisiana's cannabis operations now open at LSU agricultural center
seekingalpha.com - April 16 at 3:21 PM
GB Sciences Louisiana Receives All Approvals and Announces the Opening of the Full Tissue Propagation Cannabis Cultivation at LSU Agricultural CenterGB Sciences Louisiana Receives All Approvals and Announces the Opening of the Full Tissue Propagation Cannabis Cultivation at LSU Agricultural Center
finance.yahoo.com - April 16 at 7:16 AM
Today: GB Sciences Use of Controlled Cultivation, Product Formulations and Research Will Be Presented by Dr. Dominick Monaco at Cannabis Conference 2019, As Featured on Cover of Cannabis Business TimesToday: GB Sciences' Use of Controlled Cultivation, Product Formulations and Research Will Be Presented by Dr. Dominick Monaco at Cannabis Conference 2019, As Featured on Cover of Cannabis Business Times
finance.yahoo.com - April 2 at 7:25 AM
GB Sciences Study Shows Nevadas Cannabis Strain Names Have No Correlation to Active IngredientsGB Sciences Study Shows Nevada's Cannabis Strain Names Have No Correlation to Active Ingredients
finance.yahoo.com - March 28 at 6:18 AM
In Case You Missed It: GB Sciences Approved For Full Operations In Main LSU AgCenter Production FacilityIn Case You Missed It: GB Sciences Approved For Full Operations In Main LSU AgCenter Production Facility
finance.yahoo.com - March 26 at 3:22 PM
Louisiana Agriculture Commissioner Approves GB Sciences To Begin Full Operations In Main LSU AgCenter Production FacilityLouisiana Agriculture Commissioner Approves GB Sciences To Begin Full Operations In Main LSU AgCenter Production Facility
finance.yahoo.com - March 23 at 6:13 AM
This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.